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a b s t r a c t 
Tissue inﬂammation results in the production of numerous reactive oxygen, nitrogen and chlorine species,
in addition to the products of lipid and sugar oxidation. Some of these products are capable of chemically
modifying amino acids. This in turn results in changes to the structure and function of proteins. Increasing
evidence demonstrates that such oxidative post-translational modiﬁcations result in the generation of neo-
epitopes capable of eliciting both innate and adaptive immune responses. In this paper, we focus on how free
radicals and related chemical species generated in inﬂammatory environments modulate the antigenicity
of self-proteins, resulting in immune responses which involve the generation of autoantibodies against key
autoantigens in autoimmune diseases. As examples, we will focus on Ro-60 and C1q in systemic lupus ery-
thematosus, along with type-II collagen in rheumatoid arthritis. This review also covers some of the emerging
literature which demonstrates that neo-epitopes generated by oxidation are conserved, as exempliﬁed by
the evolutionarily conserved pathogen-associated molecular patterns (PAMPs). We discuss how these ob-
servations relate to the pathogenesis of both human autoimmune diseases and inﬂammatory disease, such
as atherosclerosis. The potential for these neo-epitopes and the immune responses against them to act as
biomarkers or therapeutic targets is also discussed. 
c © 2014 The Authors. Published by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license
( http: // creativecommons.org / licenses / by-nc-nd / 3.0 / ). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Introduction 
The breakdown of immune tolerance – and subsequent produc-
tion of antibodies against host macromolecules – is a complex pro-
cess involving genetic and environmental factors, as well as B and T
cell dysregulation. However, a key feature in the initiation of many
autoimmune diseases is the post-translational modiﬁcation of anti-
gens, which results in the recognition of host proteins as ‘non-self ’ or
‘dangerous ’ and thus the initiation of an adaptive immune response.
Oxidative stress is a key feature of many inﬂammatory autoimmune
diseases and results in an excess of reactive chemical species that are
able to post-translationally modify proteins, potentially forming neo-
epitopes [ 1 –8 ]. These neo-epitopes may directly elicit an adaptive
immune response or inﬂuence well-accepted immunological phe-
nomena such as molecular mimicry (a host antigen being ‘seen ’ as a
‘non-self ’ protein), exposure of cryptic epitopes (exposure of amino
acid sequences after changes in the three-dimensional structure of
a protein), epitope spreading (spreading of antigenicity from a given* Corresponding author. 
E-mail address: p.g.winyard@exeter.ac.uk (P.G. Winyard). 
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http://dx.doi.org/10.1016/j.redox.2014.05.004 epitope to other parts of the protein or other proteins) and the cou-
pling of an autoantigen to an exogenous antigen [ 9 –11 ]. All of the
above results in breakdown of immune tolerance. 
Neo-epitopes are able act as pathogen- or danger-associated
molecular patterns (PAMPs / DAMPs) and are sensed by the immune
system via pattern recognition receptors (PRRs) such as scavenger re-
ceptors, receptor of advanced glycation endproducts (RAGE), Toll-like
receptor 4 (TLR-4) or natural (IgM isotype) antibodies [ 12 –14 ]. This
subject has been extensively reviewed in the context of atheroscle-
rosis [ 14 ]. Increased generation of neo-epitopes / PAMPs / DAMPs may
therefore serve as a mechanism for increased uptake and presentation
of autoantigens to the immune system. Prolonged / repeated exposure
of antigens to the immune system in this way is a known route for
the initiation of class switching in the adaptive immune response
[ 15 –18 ]. 
Oxidative modiﬁcations are not the only post-translational mod-
iﬁcations (PTMs) that may initiate autoantigenicity. Enzymatic PTMs
are well-documented. For example, the ability of granzyme B to pro-
teolytically cleave a particular protein (thereby generating antigenic
cleavage products) is a predictor of autoantigenicity [ 19 ]. Another
well-known example of enzymatic PTMs is the citrullination of argi-
nine by peptidyl arginine deiminase (PAD), forming citrulline. This
PTM generates epitopes that provide a highly sensitive and speciﬁc
 open access article under the CC BY-NC-ND license ( http: // creativecommons.org / 
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 ssay for the diagnosis of rheumatoid arthritis (RA; discussed in de- 
ail below) [ 20 , 21 ]. Other modiﬁcations include the methylation of 
pliceosomal proteins in systemic lupus erythematosus (SLE) and the 
eamidation of the coeliac autoantigen, gliadin, by transglutaminase 
 22 , 23 ]. This subject has previously been reviewed elsewhere [ 24 ]. 
Oxidative modiﬁcations of DNA, proteins and lipids all increase 
heir antigenicity with relevance to both autoimmune and other dis- 
ases with an inﬂammatory component. Whilst there is no doubt that 
n autoimmune diseases such as RA, SLE and type-1 diabetes melli- 
us (T1D) the generation IgG isotype autoantibodies plays a direct 
ole in pathogenesis, there is an increasing appreciation of the po- 
ential role of ‘natural ’ IgM isotype autoantibodies in the early stages 
f autoimmune triggering. Indeed, it is estimated that 30% of all nat- 
ral IgM antibodies, secreted by a subset of B cells (B1 cells), target 
xidation-speciﬁc epitopes and may act to neutralise both pathogens 
nd neo-epitopes [ 25 ]. 
The methods for the measurement of antibodies to oxidatively 
odiﬁed proteins in autoimmune diseases, and subsequent assess- 
ent of their clinical utility, have been described elsewhere [ 26 , 27 ]. 
his review will detail examples of how oxidation, nitration, lipid 
eroxidation and advanced glycation end-product formation inﬂu- 
nce the breakdown of tolerance towards proteins in autoimmune 
iseases, with SLE and RA as primary exemplars. 
odiﬁcation of proteins by free radicals and other reactive 
pecies 
eactive oxygen, nitrogen and chlorine species 
A number of cellular processes and enzymes are capable of gen- 
rating reactive oxygen, nitrogen and chlorine species in vivo , in re- 
ponse to a wide variety of stimuli during homeostasis and during 
nﬂammation. The enzymatic generation of free radicals and other 
eactive species is largely governed by enzyme expression / activity, 
ubcellular localisation and the presence of cofactors, whereas non- 
nzymatic reactive species generation is usually stochastic in nature. 
uring inﬂammation, phagocyte NADPH oxidase (NOX2), inducible 
itric oxide synthase (iNOS), and myeloperoxidase (MPO) all act as 
ajor sources of reactive oxygen, nitrogen and halide species capable 
f modifying proteins or generating secondary electrophilic species 
uch as lipid peroxidation products and products of glucose oxidation. 
 wide variety of amino acids are susceptible to modiﬁcation by these 
eactive species. The types of modiﬁed amino acids are governed by a 
umber of factors including the rate constant for the reaction between 
he oxidant and the given amino acid residue, the solvent exposure 
f the target residue, steric hindrance of the target residue, the pKa of 
he residue and the identity of the surrounding residues. In relation to 
ntibody production, solvent-exposed neo-epitopes are more likely 
o initiate an immune response. 
A range of reactive oxygen, nitrogen and chlorine species are ca- 
able of modifying proteins, including the hydroxyl radical ( •OH), the 
arbonate radical (CO 3 
•−), hypochlorite (OCl −) and products formed 
rom reactions involving peroxynitrite (ONOO −). Cysteine residues 
n proteins are readily oxidised due the free thiol (–SH) group. This 
ree thiol may be oxidised to form either an inter- or intra-molecular 
isulﬁde bond with another free thiol ( −S −S −). In addition, cys- 
eine may be oxidised to cysteine sulfenic, sulﬁnic and sulfonic acid 
erivatives ( Fig. 1 a). This occurs in the presence of oxidants such as 
OH and is used by antioxidant systems such as the peroxiredoxin / 
hioredoxin system [ 28 , 29 ]. Importantly, cysteine is a target of S- 
itrosation. Although this modiﬁcation is important for cellular sig- 
alling, S-nitrosothiols are unlikely to represent neo-epitopes capable 
f eliciting an immune response, given the labile nature of the S −NO 
ond ( Fig. 1 a). Similarly, methionine can be oxidised to methionine 
ulfoxide and further to methionine sulfone ( Fig. 1 b) [ 30 ]. Other ox- 
dative modiﬁcations to amino acids include tryptophan oxidation to hydroxytryptophan and further to kynurenine ( Fig. 1 c), and tyrosine 
oxidation to 3,4-dihydroxyphenylalenine, or inter- or intra-molecular 
di-tyrosine cross-linking via the formation of tyrosyl radicals ( Fig. 1 d) 
[ 31 , 32 ]. 
Nitration of tyrosine and tryptophan residues in inﬂamed tissues 
has been extensively reported in the literature and has been demon- 
strated to modulate the structure and function of proteins in many 
disease states. The relatively stable nature of the modiﬁcation in- 
dicates it may be a good candidate for neo-antigen formation ( Fig. 
1 d) [ 33 , 34 ]. Chlorination of proteins, mediated by HOCl production 
by MPO is another modiﬁcation that can occur on proteins, altering 
their function. Chlorination has been most widely reported on tyro- 
sine residues, forming 3-chlorotyrosine. Chloramines on lysine and 
histidine residues constitute important intermediates in stable end 
products of chlorination ( Fig. 1 d) [ 35 , 36 ]. It is this chlorination of pro-
teins and DNA that is responsible for the effects of MPO-derived HOCl 
during the respiratory burst [ 37 ]. 
Lipid peroxidation products 
Oxidation of unsaturated double bonds in lipids, by species such 
as •OH can result in the formation of lipid peroxyl radicals (RO 2 •). 
These radicals can then act on other unsaturated lipids to propagate 
lipid peroxidation. This lipid peroxidation can disrupt cell membranes 
leading to necrosis or the induction of apoptosis of cells, through mod- 
iﬁcation of DNA or proteins. Two major reactive species produced 
by lipid peroxidation at sites of inﬂammation are malondialdehyde 
(MDA) and 4-hydroxynonenal (4-HNE) ( Fig. 2 a), both of which are ca- 
pable of reacting with a number of (nucleophilic) amino acid residues 
in proteins, including lysine, arginine, methionine, tyrosine and his- 
tidine, primarily through 1,4 Michael addition reactions [ 38 , 39 ]. 
Products of glucose oxidation 
The reactive electrophiles, glyoxal and methylglyoxal, are formed 
from the oxidation of glucose, a process that is increased under oxida- 
tive stress. The reaction of glyoxal and methylglyoxal with proteins 
results in the formation of AGEs such as pentosidine, which are asso- 
ciated with a number of inﬂammatory pathologies ( Fig. 2 b) [ 40 , 41 ]. 
These AGEs are formed through the Maillard reaction between reac- 
tive carbonyls and basic amino acid side chains such as lysine and 
arginine. AGEs have been implicated in a number of diseases. For ex- 
ample, serum levels of pentosidine are increased in both RA and SLE 
patients [ 42 ]. 
Systemic lupus erythematosus 
Autoantigen reservoirs within uncleared apoptotic cells in SLE patients 
SLE is a prototypic systemic autoimmune disease affecting mul- 
tiple organs of the body. The clinical features of SLE are primarily 
a result of inﬂammation mediated by autoantibodies against host 
macromolecules, such as DNA and proteins. Autoantibodies form im- 
mune complexes with host molecules. These immune complexes can 
be deposited in the glomeruli of the kidney and in other organs caus- 
ing inﬂammation. 
Whilst the reason for the breadth of both cellular and periph- 
eral antigens recognised in SLE patients is unknown, Casciola-Rosen 
et al. [ 43 ] demonstrated that a large number of lupus autoantigens 
are expressed on the surface of apoptotic cells and clustered in close 
proximity to oxidant-generating sites such as the endoplasmic retic- 
ulum. Later, it was demonstrated that enzymatic cleavage of a given 
protein by the serine protease, granzyme B, was a predictor of au- 
toantigenicity and further that levels of granzyme B secreting CD8 + 
T-cells correlated with disease activity in SLE patients [ 19 , 44 ]. This 
observation is supported by the observed accumulation of apoptotic 
cells in the peripheral blood of SLE patients, indicating impairment 
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Fig. 1. Structures of amino acids after post-translational modiﬁcations by reactive oxygen, nitrogen and chlorine species. Structures of some of the post-translationally modiﬁed 
forms of (a) cysteine residues, (b) methionine residues, (c) tryptophan residues and (d) tyrosine residues. 
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Fig. 2. Structures of some lipid and glucose oxidation products, and examples of the products formed by reactions of lipid / glucose oxidation products with amino acids within 
proteins – thereby generating post-translational modiﬁcations. Structures of (a) lipid peroxidation products (b) a product of lysine modiﬁcation by MDA, (c) structures of the 
products of glucose oxidation, glyoxal and methylglyoxal, and (d) the AGEs carboxymethyllysine and pentosidine. 
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tn the clearance of these apoptotic cells (impairment of efferocyto- 
is) and the consequent presence of a reservoir of autoantigens as- 
ociated with apoptotic cells. The uncleared apoptotic cells undergo 
econdary necrosis, a loss of membrane integrity and the spillage of 
ntracellular proteins into the extracellular space [ 45 , 46 ]. Thus, in SLE 
atients there is a vicious cycle of oxidant generation and necrotic 
ell formation that stimulates the autoimmune response. It is there- 
ore interesting to note that many of the same molecules which are 
esponsible for the uptake of apoptotic cells also act as receptors for 
xidised autoantigens e.g. CD36, RAGE and C-reactive protein [ 47 , 48 ]. 
eo-epitope formation and epitope spreading in nuclear antigens 
Oxidative stress is prevalent in SLE patients, as evidenced by an in- 
rease in oxidatively modiﬁed amino acids such as increased methio- 
ine sulfoxide, 3-nitrotyrosine and protein carbonyls, and decreased 
rotein thiols. Indeed, levels of a number of these oxidatively mod- 
ﬁed amino acids correlated with disease activity [ 6 , 7 , 49 ]. Similarly, 
LE patients have raised serum levels of MDA- and 4-HNE-modiﬁed 
roteins as well as AGEs [ 50 , 51 ]. In addition, antibody titres against 
DA- and 4-HNE-modiﬁed ovalbumin were found to be raised in 
LE patients and also correlated with disease activity. Modiﬁcation of 
ovine serum albumin with polyunsaturated fatty acids resulted in 
ross-reactivity with sera from MRL- lpr mice, with 4-oxo-2-nonenal 
odiﬁcation being identiﬁed as the main antigenic determinant [ 52 ]. 
owever, a subset of anti-dsDNA antibodies from these mice also 
ound 4-oxo-2-nonenal-modiﬁed bovine serum albumin, indicating 
ross-reactivity between dsDNA and oxidatively modiﬁed antigens 
 52 ]. 
Approximately 90% of SLE patients have antibodies to nuclear 
omponents or phospholipids at the time of diagnosis, indicating 
hat the development of autoantibodies precedes the onset of clinical symptoms [ 53 ]. 4-HNE modiﬁcation of the SLE and Sj ¨ogren’s syn- 
drome antigen, Ro-60, results in autoimmunity and the development 
of a lupus-like phenotype in rodent models. The extent of the mod- 
iﬁcation of the Ro-60 appears to dictate whether a SLE or Sj ¨ogren’s 
syndrome phenotype is observed [ 11 , 54 ]. Interestingly, the genetic 
background of the mice, injected with Ro-60, signiﬁcantly alters the 
observed phenotype [ 55 ]. This is an interesting observation in the 
context of the heterogeneity of SLE patients with similar autoanti- 
body proﬁles. 
Neo-epitope formation in non-nuclear antigens 
The ﬁrst component of complement, C1q, has been shown to par- 
ticipate in both the initiation of the complement cascade and in effero- 
cytosis, two processes that are known to be important in SLE patho- 
genesis [ 46 , 56 , 57 ]. In addition, autoantibodies to C1q are strongly 
associated with the development of nephritis in SLE patients [ 58 –
60 ]. The oxidative modiﬁcation of C1q is capable of increasing the 
antigenicity of the molecule and antibody titres towards oxidatively 
modiﬁed C1q, but not native C1q, correlate with renal disease severity 
in these patients [ 61 –63 ]. 
Autoantibodies to MDA-modiﬁed epitopes are more prevalent in 
SLE patients than healthy control subjects These antibodies were 
determined to be predominantly of the IgM isotype when MDA- 
modiﬁed bovine serum albumin was used as the target antigen [ 64 ]. 
SLE patients have raised levels of IgG and IgM antibodies to MDA- 
modiﬁed low-density lipoprotein (LDL) compared to healthy subjects, 
whereas IgG anti-MDA-LDL levels were higher in SLE patients with 
cardiovascular disease than those without [ 65 ]. In addition, SLE pa- 
tients demonstrate a higher level of oxidised LDL than healthy control 
subjects and both IgM and IgG reactivity correlated with disease activ- 
ity [ 66 ]. These results suggest the systemic presence of IgM and IgG 
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Fig. 3. Schematic representation of the role of oxidative PTMs in the initiation of autoimmunity. 1. Oxidants generated during inﬂammation modify amino acids in proteins 
known to be key antigens in inﬂammatory and autoimmune diseases. 2. These modiﬁed proteins or lipids represent neo-antigenic determinants that constitute neo-epitopes 
or pathogen / danger associated molecular patterns (PAMPs / DAMP)s and are recognised by the innate immune system via pattern recognition receptors (PRRs) such as toll-like 
receptors or scavenge receptors e.g. SR-A. 3. It appears that these neo-antigenic determinants result in an innate immune response, probably mediated by B1 cells resulting in 
production of IgM, which itself may act as a PRR. 4. IgM acts in a protective manner, possibly neutralising the ‘neo-antigen ’ . 5. Neo-epitope formation aids in the breaking of 
tolerance and an adaptive (IgG) immune response ensues, followed by epitope spreading. 6. Production and binding of these autoantibodies to their antigens result in loss of protein 
function, cell / tissue damage and inﬂammation, which increases the production of free radicals and other reactive species. See text for references. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 antibodies to MDA-modiﬁed autoantigens in SLE patients, and also
suggest that MDA modiﬁcation of LDL may be an important route of
LDL modiﬁcation in atherosclerosis. Indeed, expression of the natu-
ral antibody ppc1-5, which recognises both DNA and oxidised bovine
serum albumin, elicited a protective effect in lupus prone mice (MRL-
lpr), reducing immune complex deposition and proteinuria [ 67 , 68 ].
These beneﬁts were associated with increased production of the anti-
inﬂammatory cytokine, IL-10. 
The data summarised above supports the hypothesis that oxida-
tively modiﬁed proteins elicit an innate (predominantly IgM) immune
response. Upon prolonged exposure to this neo-antigen, an adaptive
(IgG) response is mounted followed by epitope spreading to non-
modiﬁed epitopes and eventually to other proteins complexed with
the initial antigen (as summarised in Fig. 3 ). 
Rheumatoid arthritis 
Post-translational modiﬁcations involving citrullination and carbamyla-
tion 
The most widely used clinical test for the diagnosis of RA is
the measurement of anti-cyclic citrullinated peptide antibodies [ 20 ].
Some of the peptides, used in the original assay derived from proteins
such as vimentin and ﬁbrinogen, contain arginine residues. Arginine
can undergo PTM to citrulline, catalysed by the enzyme peptidyl argi-
nine deiminase (PAD) ( Fig. 4 a) [ 5 , 21 , 69 ]. In addition, carbamylation of
proteins results in conversion of lysine to homocitrulline resulting in
the loss of the positive charge of the lysine side chain, a process me-
diated by MPO catalysed cyanate formation ( Fig. 4 b and c). Carbamy-
lation has been demonstrated to alter protein function, for example,LDL carbamylation inﬂuences inﬂammation via scavenger receptor A,
albumin carbamylation inhibits a type-I collagen-induced respiratory
burst, and MMP-9 activity can be altered by carbamylation of collagen
(resulting in a modulation of extracellular matrix turnover) [ 70 –72 ].
Given the structural similarity between citrulline (generated by PAD
activity) and homocitrulline (a modiﬁcation of lysine residues medi-
ated by MPO catalysed cyanate formation), anti-citrullinated protein
antibodies may also bind homocitrullinated antigens [ 73 ]. In addi-
tion, not all anti-carbamylated protein antibodies are expected to
cross-react with citrullinated epitopes as antibody binding may be
dependent on structural epitopes. Identiﬁcation of cross-reactivity
between the two has the potential for identifying subsets of RA pa-
tients [ 74 ]. 
Oxidative modiﬁcation of rheumatoid factor 
Additionally, many RA patients demonstrate the presence of
rheumatoid factor (RF; antibodies targeting the Fc region of IgG) [ 20 ].
Although glycated IgG was detected in a number of inﬂammatory
diseases, an increased proportion of RF-positive RA patients demon-
strate antibodies to glycated IgG, compared to RF-negative patients
[ 75 ]. In addition, IgG modiﬁed by a number of reactive oxygen species
(ROS)-generating systems is a target for IgM isotype antibodies in RF-
positive RA and SLE patients [ 76 ]. Oxidation of IgG impairs its function,
altering both C1q and Fc receptor binding [ 77 –79 ] Indeed, immuni-
sation of rabbits with hydroxyl radical modiﬁed IgG induces a cross-
reactive immune response mounted against IgG, nuclear components,
as well as other antigens demonstrating that ROS may contribute to
antibody cross-reactivity as observed in autoimmune diseases such
as RA and SLE [ 80 ]. 
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Fig. 4. Schematic representation of (a) citrullination of arginine by peptidyl arginine deiminase (PAD); (b) myeloperoxidase (MPO)-catalysed cyanate generation by oxidation of 
thiocyanate; and (c) conversion of lysine to homocitrulline by cyanate derived from the MPO-catalysed oxidation of thiocyanate to cyanate. 
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ﬂutoantibodies to modiﬁed type-II collagen 
Type-II collagen (CII) is one of the major autoantigens in the RA. 
e have demonstrated that modiﬁcation of CII by oxidants including 
OH, HOCl, ONOO − or glycation with ribose, increases the antigenicity 
f CII and results in aggregation and / or cleavage of the molecule [ 81 ]. 
n addition, antibodies to HOCl-modiﬁed CII are speciﬁc biomarkers 
f RA [ 82 ]. A greater proportion of early RA patients exhibited anti- 
odies to HOCl-modiﬁed CII (90%) compared to unmodiﬁed CII (18%). 
urthermore, the number of patients with anti-modiﬁed CII antibod- 
es was higher in patients who did not respond to disease-modifying 
nti-rheumatic drugs (DMARDs; e.g. methotrexate) compared to pa- 
ients who responded to DMARDs [ 82 ]. 
ype 1 diabetes 
Serum autoantibodies in patients with autoimmune, type I, di- 
betes recognise H 2 O 2 / CuCl 2 induced aggregates of glutamic acid 
ecarboxylase (GAD) [ 83 ]. Recently, we [ 84 ] demonstrated that ox- 
dative modiﬁcation signiﬁcantly increased the antigenicity of CII in 
ype-I diabetes patients that carried the HLA-DRB1*4 allele associ- 
ted with increased RA prevalence, but to a lesser extent in patients 
ithout the RA associated HLA-DRB1*4. These data indicate a role of 
xidative PTMs in autoimmunity in type-I diabetes patients. 
ther chronic diseases with an autoimmune component 
Chronic obstructive pulmonary disease (COPD) is an inﬂammatory 
isease in which oxidative stress and the production of lipid peroxi- 
ation products play a key pathogenic role (as reviewed [ 8 ]). Indeed, 
OPD patients produce IgG1 isotype autoantibodies to carbonylated 
roteins [ 85 ]. The titre correlates with disease severity as does in- 
ammatory C3 deposition in the lung [ 86 ]. 3-Nitrotyrosine formation has been found to be prevalent in a 
number of cancers. The presence of 3-nitrotyrosine acts as a marker 
of the ability of CD8 + cells to respond to therapy in prostate cancer 
[ 87 , 88 ]. Despite the absence of IgG autoantibodies in cancer patients, 
large numbers of unmutated IgM molecules can be detected, indicat- 
ing a role of immune surveillance in cancer progression [ 89 –91 ]. 
An increased risk of atherosclerosis has been identiﬁed in RA, 
SLE, scleroderma and T1DM patients [ 92 –95 ]. Research into both 
classical autoimmune diseases and the innate / adaptive immune re- 
sponses in atherosclerosis provides informative parallels. The for- 
mation of oxidised LDL (oxLDL) is a key process in the aetiology 
of atherosclerosis. Both IgG and IgM isotype antibodies targeting 
oxLDL have been extensively described in these patients, with IgM 
isotype antibodies providing protection from the disease and the 
presence of IgG isotype antibodies being associated with a poorer 
prognosis [ 96 ]. IgM antibodies from atherosclerosis patients such as 
T15 / E06 target the oxidised lipid moieties of LDL such as the phos- 
phatidylcholine oxidation products 1-palmitoyl-2-(5-oxovaleroyl)- 
sn -glycero-3-phosphocholine (POVPC) and 1-palmitoyl-2-glutaroyl- 
sn -glycero-3-phosphocholine (PGPC) ( Fig. 5 ) [ 97 –99 ]. Recently, it has 
been demonstrated that antibodies to oxidised high-density lipopro- 
tein (HDL) also exist in atherosclerosis patients. The oxidation of HDL 
emanates from an MPO-halide dependent oxidation of a tryptophan 
residue, forming 2-hydroxytryptophan ( Fig. 1 c) [ 100 ]. Interestingly, 
these anti-HDL antibodies target the protein moiety of the lipoprotein, 
as opposed to the lipid moiety, demonstrating the ability of antibodies 
to target both protein and lipid modiﬁcations in structurally similar 
molecules. 
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Fig. 5. Structures of (a) the unmodiﬁed phosphatidylcholine molecule (16:0 / 20:4 PC) and (b) the oxidised lipid product 1-palmitoyl-2-(5-oxovaleroyl)- sn -glycero-3- 
phosphocholine (POVPC; 16:0 / 5:0 PC). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Future directions and challenges 
Oxidative modiﬁcations as innate immune triggers 
The oxidative PTM of host proteins is a frequent and necessary
phenomenon required for processes such as cell signalling. However
the nature of these modiﬁcations is usually reversible (e.g. cysteine
sulfenic acid, S-nitrosothiol and methionine sulfoxide formation) and
it may be conjectured that they probably do not usually initiate an
immune response. In the case of stable PTMs, the chronic exposure
to these post-translationally modiﬁed neo-epitopes / PAMPs may be
enough to trigger the breakdown of tolerance in individuals with un-
derlying impaired immune regulation. The observation that a large
number of established innate PRRs, such as CD36, CRP and IgM, all
recognise various oxidatively modiﬁed antigens indicates evolution-
arily conserved mechanisms that are shared by both ‘self ’ and ‘foreign ’
PAMPs [ 101 ] ( Fig. 3 ). The role of these innate immune sensors of neo-
epitopes in autoimmunity remains to be elucidated, although the
increasing number of examples of both innate and adaptive immune
responses to neo-antigens indicates that these observations could
translate into diagnostic and therapeutic beneﬁts. However, both the
identiﬁcation and the proposed manipulation of the B1 cells thought
to be responsible for this IgM secretion remain contentious issues
[ 102 ]. 
Given the data available, it may be suggested that the key impair-
ment in inﬂammatory autoimmune diseases is either the chronic pro-
duction of neo-antigens or the dysregulation of the interface between
‘protective ’ IgM responses and ‘pathogenic ’ IgG responses. This leads
to the hypothesis that in diseases such as RA and SLE (particularly pa-
tients with atherogenesis), increasing IgM titres are produced, over
time, in response to sustained presentation of oxLDL to B cells. How-
ever, chronic presentation of oxLDL by antigen presenting cells (APCs)
to B cells, or increasing amounts of oxLDL, in a pro-inﬂammatory envi-
ronment, may initiate an IgG anti-oxLDL response. Interestingly, T15
antibodies responsible for binding to oxLDL are also able to recog-
nise oxidised phospholipids expressed on the surface of apoptotic
cells [ 97 ]. Given the well-established observations, both of defective
apoptotic cell clearance in SLE patients and increased incidence of
atherosclerosis in SLE patients (see discussion above), the potential
for B1-cell-mediated natural antibody production in SLE warrants
further investigation.  
 
 Clinical utility of responses against neo-epitopes 
Modiﬁcation of proteins by oxidants generates a wide variety of
products, as described above. Whether there is a speciﬁc disease “ﬁn-
gerprint” of PTMs / sequences that is associated with modiﬁed anti-
genicity in particular diseases (possibly in combination with genetic
background) remains to be investigated, although the solvent expo-
sure of neo-epitopes likely plays a major role [ 55 , 103 ]. Aside from
neo-epitope formation, oxidative modiﬁcations may affect the struc-
ture of a protein, resulting in unfolding [ 104 ]. This, in turn, exposes
cryptic epitopes which are able to elicit an immune response [ 10 ].
Autoantibodies to oxidatively modiﬁed autoantigens have been iden-
tiﬁed in a number of autoimmune inﬂammatory diseases and there
are increasing literature examples of the titres of these antibodies be-
ing biomarkers, as described above. Indeed, these neo-antigens have
the potential to act as early and / or speciﬁc disease biomarkers. The
demonstration that oxidative PTMs of major autoantigens in RA and
SLE increases antigenicity has clear mechanistic implications for the
aetiology of these diseases, but whether the presence of anti-oxidised
protein antibodies is, in general, an epiphenomenon in the wider con-
text of inﬂammatory disease remains to be elucidated. 
A major challenge encountered in studies of neo-antigenicity is
the identiﬁcation of the peptide sequence / structural motifs contain-
ing the modiﬁed amino acid residue (antigenic determinant). A num-
ber of studies have reported interesting correlations between disease
activity and antibody titres, using whole proteins modiﬁed with a
promiscuous oxidant, as discussed above. The identities of the ex-
act neo-epitope and antigenic determinants responsible for autoim-
munity are difﬁcult to determine, although progress will be pos-
sible using a combination of LC–MS / MS, molecular modelling and
peptide-based ELISA approaches [ 26 , 27 , 62 ]. Once neo-epitopes have
been identiﬁed, it is possible to develop diagnostic assays based only
on the clinically-relevant epitope(s) – as opposed to whole proteins
that may contain additional, confounding (non-clinically-relevant),
epitopes. Assays based solely on clinically-relevant neo-epitopes are
likely to exhibit higher clinical sensitivity and speciﬁcity, as exempli-
ﬁed in the development of the anti-CCP assay [ 105 ]. 
The heterogeneity of immune responses is a major factor in iden-
tifying immune responses in autoimmune diseases such as RA and
SLE. For example antibodies to citrullinated antigens are an excellent
diagnostic marker of RA, although not all RA patients are positive
for anti-citrullinated peptide antibodies. Similarly, antibodies to PTM
antigens may identify clinically-relevant sub-populations of patients
such as patients who are likely not to respond to DMARDs, or biologics.
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Rhis principle is demonstrated by the case of HOCl-modiﬁed CII, dis- 
ussed above [ 82 ]. Despite these potential advances, no single native 
r PTM antigen is likely to provide a deﬁnitively speciﬁc or sensitive 
linical diagnosis or prognosis for polygenic conditions. Thus substan- 
ial clinical gains may be made by multiplexing assays – measuring 
mmune responses against a number of native and PTM antigens – to 
evelop more robust multi-biomarker diagnostic scores. 
B-cell depletion therapy potentially offers a unique chance to iden- 
ify the role of PTMs in the mechanism of autoantibody production, 
ssuming the mechanism is identical in disease initiation and during 
 cell repopulation. For example, longitudinal samples could be taken 
rom SLE patients who have received B cell depletion therapy and are 
n a subsequent phase of B cell repopulation. If anti-PTM antibody 
itres were observed to precede antibody production against the na- 
ive antigen (as suggested by data using HNE-modiﬁed Ro-60 in SLE, 
ee above) this would implicate PTMs in the breaking of tolerance to 
hat antigen. 
A step towards translating our understanding of PTM mechanisms 
o therapeutic applications is the identiﬁcation and cloning of both 
uman anti-oxLDL and anti-oxHDL antibodies using phage display 
ibraries [ 100 , 101 ]. This approach has identiﬁed speciﬁc antibodies 
ecognising PTM antigens by using phage-display in conjunction with 
TM peptides as the target antigen for selection. This technique has 
een used to identify antibodies that recognise oxidatively modiﬁed 
ntigens such as T15 and IK17, and subsequently a single chain Fv 
ragment that lacks immunostimulatory capacity but will ‘neutralise ’ 
ts oxidatively modiﬁed antigen [ 101 , 106 ], and suggests a framework 
or translating the observations of oxidised protein antibodies in au- 
oimmune diseases into potential therapeutics. We have begun to 
ake steps in this direction, in the context of RA, by generating a 
ingle-chain Fv fragment which speciﬁcally recognises oxidised CII 
 82 ]. Given the general lack of efﬁcacy of clinically tested antioxidants 
n human autoimmune diseases [ 2 ], the inhibition of neo-epitope for- 
ation might be insufﬁcient to modulate disease in patients with es- 
ablished disease, if we assume that the antioxidants used in clinical 
rials were able to inhibit neo-epitope formation at the tested doses. 
owever, alternative therapeutic strategies involving the manipula- 
ion of the resulting immune responses – either targeting IgM pro- 
uction (potentially via B1 cells) or selectively targeting IgG responses 
using neutralising peptides or single chain antibody fragments) – of- 
er potential beneﬁts as well as technical challenges. 
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